Market capitalization | $3.60m |
Enterprise Value | $6.36m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-36.20m |
Cash position | $7.96m |
EPS (TTM) EPS | $-3.05 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Aptose Biosciences Inc.:
1 Analyst has issued a forecast Aptose Biosciences Inc.:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.43 -0.43 |
7%
7%
|
|
EBITDA | -36 -36 |
29%
29%
|
EBIT (Operating Income) EBIT | -36 -36 |
29%
29%
|
Net Profit | -36 -36 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Head office | Canada |
CEO | William Rice |
Employees | 35 |
Founded | 1986 |
Website | www.aptose.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.